Codexis (CDXS) Pops, Gets FDA Approval for New Stagliptin Manufacturing Process
Tweet
Share
E-mailGet Alerts CDXS Hot Sheet
Join SI Premium – FREE
Codexis, Inc. (Nasdaq: CDXS), is moving higher Wednesday after the following announcement made late Tuesday night. Shares are up about 13% early.
Codexis has announced that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia.
“FDA approval of this manufacturing process is a major milestone for Codexis,” said Peter Strumph, Interim Chief Executive Officer. “This is another example of how our directed evolution technology can deliver well controlled, cost advantaged commercial pharmaceutical, biofuel, or bio-based chemical production processes.”
Codexis has announced that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia.
“FDA approval of this manufacturing process is a major milestone for Codexis,” said Peter Strumph, Interim Chief Executive Officer. “This is another example of how our directed evolution technology can deliver well controlled, cost advantaged commercial pharmaceutical, biofuel, or bio-based chemical production processes.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU approves Acadia's trofinetide for Rett syndrome treatment
- Comstock closes $45M mining asset sale, receives $20M cash
- Hanmi Pharm licenses obesity drug to Genentech in $2.3B deal
Create E-mail Alert Related Categories
Corporate News, FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
